Caleigh has struggled most of her life with a difficult lung disease, but she never lets it get the best of her.

Thursday, Vertex Pharmaceuticals Incorporated (NASDAQ:VTRX) reported second-quarter revenues of $2.65 billion, almost in line with the consensus of estimate of $2.66 billion. Vertex Pharmaceuticals ...

Biotech companies, like Vertex Pharmaceuticals, benefit from patents, driving consistent growth. Vertex excels in cystic fibrosis treatments and boasts a promising pipeline of new drugs. Vertex's ...

Vertex Pharmaceuticals (VRTX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst David Risinger from Leerink Partners reiterated a Buy rating ...